Ocugen, Inc., an Aurora, CO- and Malvern, PA-based biopharmaceutical company developing treatments for sight-threatening diseases, closed a $6m Series A funding.
Backers included $1m in funds raised through EB5 Life Sciences and Dr. Bernhard Hampl.
The company intends to use the funds to advance the OCU300 program toward an IND submission within a year.
Led by Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder, Ocugen is developing OCU300, a repurposed drug with an established safety track record in ocular applications that is being developed for the treatment of ocular graft versus host disease (oGVHD) under the U.S. Food and Drug Agency’s 505(b)(2) regulatory pathway. Ocular GVHD is a common complication that occurs in patients who have undergone allogenic hematological stem cell transplantation (allo-SCT), or bone marrow transplants.
Ocugen has a broad pipeline which includes both clinical stage and pre-clinical programs which are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye and are designed to deliver value over the near, mid and long term.